therapeut
vaccin
current
exist
human
coronavirus
hcov
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
epidem
recent
emerg
middl
east
respiratori
syndrom
coronaviru
merscov
april
emphas
high
probabl
futur
zoonot
hcov
emerg
caus
sever
lethal
human
diseas
addit
resist
sarscov
ribavirin
rbv
demonstr
need
defin
new
target
inhibit
cov
replic
cov
express
exoribonucleas
nonstructur
protein
requir
highfidel
replic
conserv
across
cov
famili
genet
biochem
data
support
hypothesi
rna
proofread
function
thu
hypothes
exon
respons
cov
resist
rna
mutagen
demonstr
wildtyp
exon
cov
resist
rbv
cov
lack
exon
activ
sensit
primari
antivir
activ
rbv
cov
mutagenesi
cov
treat
demonstr
enhanc
sensit
multicycl
replic
well
decreas
specif
infect
consist
function
mutagen
comparison
fullgenom
nextgener
sequenc
treat
sarscov
popul
reveal
increas
number
mutat
within
popul
compar
exon
nineti
percent
mutat
repres
g
u
c
transit
consist
incorpor
rna
synthesi
togeth
result
constitut
direct
evid
cov
exon
activ
provid
critic
proofread
function
viru
replic
furthermor
studi
identifi
exon
first
viral
protein
distinct
rdrp
determin
sensit
rna
virus
mutagen
final
result
show
import
exon
target
inhibit
suggest
smallmolecul
inhibitor
exon
activ
could
potenti
pancov
therapeut
combin
rbv
rna
mutagen
potenti
cov
caus
signific
human
diseas
well
demonstr
six
known
sarscov
merscovcaus
cold
pneumonia
system
infect
sever
lethal
diseas
four
virus
identifi
last
year
two
sarscov
merscov
caus
lethal
respiratori
system
infect
studi
past
year
expand
known
phylogenet
geograph
speci
divers
cov
support
multipl
emerg
event
cov
human
bat
zoonot
pool
recent
evid
cov
transspeci
movement
come
emerg
novel
merscov
april
june
merscov
caus
laboratori
confirm
case
mortal
sever
respiratori
system
diseas
least
countri
evid
humantohuman
transmiss
merscov
close
relat
bat
cov
recent
identifi
receptor
dipeptidyl
peptidas
present
human
bat
cell
provid
compel
argument
zoonot
cov
infect
result
sever
human
diseas
may
frequent
event
previous
thought
lack
epidemiolog
data
remain
unknown
whether
multipl
introduct
zoonot
sourc
human
transmiss
mild
asymptomat
diseas
respons
continu
case
sporad
sever
infect
howev
base
high
mortal
rate
associ
sarscov
report
merscov
novel
viru
potenti
repres
seriou
threat
global
health
vaccin
therapeut
current
exist
cov
contain
largest
known
rna
genom
kb
encod
array
viral
replicas
protein
includ
exoribonucleas
exon
domain
within
nonstructur
protein
similar
proofread
subunit
e
e
coli
dna
polymeras
iii
cov
member
dedd
superfamili
dna
rna
exonucleas
superfamili
contain
four
conserv
dedd
acid
residu
requir
enzymat
activ
mutat
critic
residu
within
cov
exon
ablat
significantli
reduc
exon
activ
studi
group
demonstr
exon
activ
essenti
highfidel
replic
model
cov
murin
hepat
viru
mhv
sarscov
inactiv
exon
activ
due
alanin
substitut
first
two
activ
site
residu
result
reduc
replic
fidel
cell
cultur
reduct
sarscov
infect
vivo
associ
profound
stabl
attenu
sarscov
virul
replic
recent
studi
shown
bacteriallyexpress
sarscov
remov
mismatch
nucleotid
vitro
exon
activ
stimul
vitro
interact
nonenzymat
cov
protein
thu
bioinformat
genet
biochem
studi
date
support
hypothesi
first
identifi
proofread
enzym
rna
viru
function
togeth
cov
replicas
protein
perform
crucial
role
maintain
cov
replic
fidel
retrospect
clinic
studi
sar
epidem
ultim
conclud
treatment
ribavirin
rbv
antivir
drug
shown
mutagen
rna
virus
ineffect
sarscov
exon
activ
requir
cov
highfidel
replic
sought
determin
exon
respons
cov
resist
rna
mutagen
use
nucleosid
analog
rbv
base
analog
show
cov
lack
exon
activ
sensit
inhibit
wildtyp
cov
exon
addit
use
fullgenom
nextgener
sequenc
show
virus
accumul
g
u
c
transit
consist
incorpor
rna
synthesi
ultim
result
suggest
excit
possibl
smallmolecul
inhibitor
exon
activ
could
potenti
pancov
therapeut
especi
use
combin
rbv
rna
mutagen
murin
astrocytoma
delay
brain
tumor
cell
dbt
cell
grown
maintain
dmem
invitrogen
contain
fb
supplement
penicillin
streptomycin
hepe
amphotericin
b
vero
cell
grown
maintain
mem
invitrogen
contain
fb
supplement
penicillin
streptomycin
amphotericin
b
work
mhv
perform
use
revers
genet
infecti
clone
base
strain
work
sarscov
perform
use
revers
genet
infecti
clone
base
urbani
strain
viral
studi
use
sarscov
perform
select
agent
certifi
laboratori
use
protocol
review
approv
institut
biosafeti
committe
vanderbilt
univers
center
diseas
control
safe
studi
mainten
sarscov
compound
cell
viabil
studi
ribavirin
rbv
guanosin
gua
mycophenol
acid
mpa
obtain
sigma
rbv
made
mm
stock
solut
prepar
dmso
steril
water
respect
gua
mpa
prepar
dmso
mm
mm
stock
respect
low
concentr
mm
work
stock
prepar
need
steril
water
prior
dilut
dmem
viabil
dbt
vero
cell
assess
use
celltiterglo
promega
plate
format
accord
manufactur
instruct
dbt
vero
cell
seed
opaqu
tissu
cultur
grade
plate
dmem
contain
rbv
ad
well
achiev
concentr
indic
water
dmso
vehicl
control
perform
addit
ethanol
control
cell
death
cell
incub
either
h
cell
viabil
determin
use
verita
micropl
luminomet
promega
result
valu
normal
untreat
cell
drug
sensit
studi
plaqu
assay
subconflu
monolay
dbt
cell
plate
pretreat
min
ml
dmem
contain
vehicl
indic
concentr
rbv
mpa
gua
drug
remov
cell
infect
mhvexon
virus
moi
plaqu
form
unit
pfu
cell
singlecycl
multicycl
min
viru
remov
ml
dmem
contain
vehicl
rbv
mpa
gua
ad
well
cell
incub
either
singlecycl
multicycl
h
supernat
harvest
viru
titer
determin
plaqu
assay
dbt
cell
sarscov
studi
subconflu
monolay
vero
cell
flask
pretreat
min
dmem
contain
vehicl
rbv
drug
remov
cell
infect
either
sarsexon
virus
moi
pfucel
singlecycl
min
viru
remov
dmem
contain
vehicl
rbv
ad
back
cell
incub
h
point
supernat
harvest
viru
titer
determin
plaqu
assay
vero
cell
treat
sampl
normal
untreat
vehicl
control
valu
express
fold
chang
untreat
viru
titer
rna
virus
high
mutat
rate
mutationsnucleotideround
replic
allow
rapid
viral
adapt
respons
select
pressur
rna
virus
long
consid
unabl
correct
mistak
replic
cov
sarscov
recent
emerg
merscov
import
except
paradigm
cov
encod
exoribonucleas
activ
nonstructur
protein
propos
prevent
andor
remov
misincorpor
nucleotid
demonstr
resist
sarscov
antivir
drug
ribavirin
rbv
hypothes
exon
respons
cov
resist
rna
mutagen
use
rbv
rna
mutagen
show
cov
lack
exon
activ
highli
suscept
rbv
contrast
wildtyp
exon
cov
inhibitori
activ
virus
result
specif
incorpor
viral
rna
synthesi
lead
extens
mutagenesi
within
viral
popul
associ
profound
decreas
viru
specif
infect
result
demonstr
proofread
activ
exon
viru
replic
suggest
inhibitor
exon
activ
could
broadli
use
inhibitor
cov
replic
combin
rbv
rna
mutagen
realtim
quantit
revers
transcript
pcr
realtim
qrtpcr
viral
genom
rna
viral
rna
harvest
infect
cell
monolay
use
trizol
reagent
invitrogen
revers
transcrib
rt
use
superscript
iii
invitrogen
random
hexam
ml
mm
stock
mg
total
rna
incub
min
remain
reagent
ad
accord
manufactur
protocol
mixtur
incub
h
min
rt
reaction
perform
final
volum
ml
realtim
qrtpcr
perform
rt
product
use
appli
bioscienc
realtim
pcr
system
power
sybr
green
pcr
master
mix
life
technolog
reaction
perform
total
volum
ml
contain
ml
power
sybr
green
pcr
master
mix
ng
forward
revers
primer
ml
rt
product
dilut
viral
genom
rna
detect
use
primer
forward
acagggtggagttcccgtta
revers
acggaagcaccaccataaga
optim
gener
nt
portion
valu
normal
use
method
endogen
express
housekeep
gene
dehydrogenas
gapdh
use
primer
forward
gggtgtgaaccacgagaaat
revers
ccttccacaatgccaaagtt
optim
yield
nt
portion
gapdh
triplic
well
sampl
analyz
averag
one
valu
repres
singl
replic
minim
welltowel
variat
cycl
paramet
follow
stage
rep
min
stage
rep
min
stage
rep
sec
min
one
repres
product
treatment
verifi
melt
curv
analysi
agaros
gel
electrophoresi
viral
rna
sarsexon
infect
vero
monolay
harvest
use
trizol
reagent
revers
transcrib
rt
use
superscript
iii
describ
except
ml
random
hexam
mm
stock
mg
total
rna
final
volum
ml
reaction
four
microlit
rt
product
use
gener
overlap
kb
amplicon
viru
treat
either
mm
pcr
highfidel
polymeras
easi
agil
use
ensur
error
minim
pcr
primer
set
gener
singl
band
purifi
use
wizard
sv
gel
pcr
cleanup
system
promega
prior
sequenc
cdna
amplicon
fragment
fragmentas
neb
cluster
sequenc
illumina
cbot
gaiix
technolog
previous
describ
base
compris
read
obtain
per
viru
casava
use
demultiplex
creat
fastq
file
low
qualiti
base
end
sequenc
read
trim
use
phred
score
guid
metric
error
probabl
higher
sequenc
less
base
trim
discard
reduc
fals
align
subsequ
fals
variant
call
program
fastqclipp
http
hannonlabcshledufastxtoolkit
index
html
use
qualiti
filter
burrowswheel
align
tool
use
align
read
sarscov
exon
refer
genom
maximum
two
mismatch
per
read
base
call
posit
determin
use
samtool
pileup
inhous
script
collect
data
perposit
posit
throughout
viral
genom
base
qualiti
gather
variant
allel
rate
initi
modifi
accord
cover
read
qualiti
base
maximum
likelihood
estim
test
signific
use
wilk
theorem
addit
allel
confid
interv
calcul
output
allel
allel
statist
signific
valu
retain
consid
true
variant
variant
found
statist
signific
mani
variant
could
distinguish
background
error
thu
background
nois
caus
sequenc
error
determin
less
statist
test
appli
note
within
figur
legend
determin
use
graphpad
prism
la
jolla
ca
softwar
statist
signific
denot
determin
use
unpair
twotail
student
test
compar
either
untreat
sampl
correspond
exon
sampl
cell
viabil
studi
treat
sampl
compar
dmem
sampl
contain
dmso
rbv
shown
incorpor
ribavirin
monophosph
rmp
viral
rna
replic
presenc
proofread
enzym
would
predict
exclud
andor
remov
nucleotid
misincorpor
exon
respons
resist
phenotyp
virus
lack
exon
activ
demonstr
increas
titer
reduct
follow
rbv
treatment
compar
wildtyp
virus
contain
exon
activ
exon
test
hypothesi
examin
sensit
mhvexon
virus
rbv
singlecycl
moi
pfucel
replic
murin
astrocytoma
delay
brain
tumor
cell
dbt
cell
toxic
observ
dbt
cell
follow
treatment
mm
rbv
figur
mhvexon
virus
resist
mm
rbv
figur
viru
titer
decreas
follow
treatment
mm
rbv
capac
mm
rbv
inhibit
replic
surpris
least
higher
concentr
rbv
requir
inhibit
polioviru
chikungunya
virus
observ
could
due
longer
genom
cov
mechan
rbv
inhibit
cov
replic
rbv
exert
antivir
activ
primarili
mutagenesi
follow
incorpor
rmp
virus
exhibit
increas
sensit
multicycl
replic
test
determin
sensit
mhvexon
virus
rbv
low
multipl
infect
moi
pfucel
unexpectedli
multicycl
replic
virus
presenc
rbv
figur
indistinguish
singlecycl
replic
rbv
report
exert
antivir
activ
numer
mechan
includ
disrupt
viral
rna
synthesi
inhibit
cellular
enzym
inosin
monophosph
dehydrogenas
impdh
determin
rbv
treatment
affect
cov
rna
synthesi
perform
twostep
realtim
quantit
revers
transcript
pcr
realtim
qrtpcr
green
virus
follow
treatment
rbv
shown
dbt
cell
infect
mhvexon
presenc
absenc
rbv
viru
titer
determin
plaqu
assay
genom
rna
level
determin
use
twostep
realtim
qrtpcr
primer
determin
viral
genom
rna
level
presenc
absenc
rbv
similar
figur
mhvexon
titer
unaffect
wherea
dosedepend
reduct
titer
follow
rbv
treatment
figur
fill
bar
correspond
dosedepend
reduct
genom
rna
observ
figur
hatch
bar
follow
rbv
treatment
demonstr
treatment
mm
rbv
decreas
rna
synthesi
nearli
replic
rbv
caus
decreas
rna
synthesi
virus
calcul
rel
specif
infect
virus
rbv
concentr
tabl
rel
specif
infect
virus
decreas
follow
treatment
rbv
mhvexon
virus
unaffect
addit
decreas
viral
rna
synthesi
rbv
could
exert
antivir
activ
competit
inhibit
impdh
rmp
test
possibl
mechan
treat
mhvexon
virus
specif
impdh
inhibitor
mycophenol
acid
mpa
singleand
multicycl
replic
concentrationdepend
decreas
viru
titer
observ
follow
mpa
treatment
singlecycl
replic
figur
mhvexon
titer
reduc
less
consist
observ
follow
rbv
treatment
figur
similar
rbv
increas
sensit
virus
mpa
observ
multicycl
replic
rbv
act
via
imdph
inhibit
addit
extracellular
guanosin
gua
restor
viru
titer
demonstr
previous
dengu
viru
addit
mm
gua
follow
rbv
mpa
pretreat
viral
infect
effect
mhvexon
virus
figur
complet
restor
titer
even
continu
presenc
mm
rbv
mm
mpa
figur
data
indic
antivir
activ
rbv
virus
occur
least
part
decreas
viral
rna
synthesi
inhibit
impdh
primari
goal
test
role
prevent
andor
remov
nucleotid
misincorpor
investig
rbv
specif
inhibit
virus
howev
result
show
presenc
exon
activ
capabl
prevent
rbv
inhibit
cov
replic
increas
sensit
virus
treatment
consist
mutagenesi
next
examin
sensit
mhvexon
virus
pyrimidin
base
analog
shown
mutagen
mani
rna
virus
treatment
dbt
cell
mm
result
detect
cellular
toxic
figur
follow
treatment
mm
figur
singlecycl
infect
mhvexon
titer
inhibit
less
titer
decreas
fold
repres
increas
sensit
compar
mhvexon
multicycl
replic
mhvexon
viru
titer
reduc
less
follow
treatment
show
reduct
titer
figur
viru
undetect
plaqu
assay
concentr
mm
analysi
viral
rna
synthesi
twostep
realtim
qrtpcr
demonstr
mhvexon
rna
level
reduc
follow
treatment
treatment
result
minim
twotof
fold
decreas
rna
figur
specif
infect
decreas
follow
treatment
mm
mm
respect
tabl
result
demonstr
exon
activ
confer
resist
support
hypothesi
drive
increas
genom
mutagenesi
viru
popul
lead
lethal
mutagenesi
extinct
determin
whether
sarscov
virus
lack
exon
activ
also
inhibit
rbv
infect
vero
cell
either
sarsexon
virus
presenc
absenc
rbv
treatment
vero
cell
mm
rbv
decreas
cell
viabil
figur
recent
report
optim
amplifi
nt
region
chang
genom
rna
level
shown
rel
endogen
gapdh
express
normal
rna
level
describ
lack
rbv
uptak
vero
cell
due
absenc
specif
equilibr
nucleosid
transport
addit
previou
studi
shown
rbv
fail
inhibit
sarscov
replic
vero
cell
consist
report
experi
sarsexon
virus
unaffect
treatment
mm
rbv
figur
therefor
perform
subsequ
experi
sarsexon
titer
reduc
follow
treatment
mm
respect
figur
contrast
titer
reduc
mm
figur
similar
virus
mm
viru
inhibit
singl
replic
cycl
repres
increas
sensit
compar
sarsexon
virus
thu
data
indic
increas
sensit
cov
rna
mutagen
absenc
exon
activ
conserv
across
divers
member
cov
famili
interest
studi
sarsexon
also
indic
exonmedi
protect
nucleotid
misincorpor
overcom
higher
concentr
mutagen
studi
rna
virus
lymphocyt
choriomening
viru
lcmv
footandmouth
diseas
viru
fmdv
vesicular
stomat
viru
vsv
demonstr
incorpor
monophosph
fump
replic
viral
rna
thu
increas
genom
mutat
determin
whether
caus
increas
mutagenesi
sarscov
popul
perform
fullgenom
ng
analysi
viru
popul
replic
presenc
absenc
analyz
entir
spectrum
mutat
aris
replic
extract
total
intracellular
rna
vero
cell
infect
either
sarsexon
virus
follow
treatment
either
mm
mm
gener
overlap
cdna
amplicon
approxim
kb
length
sampl
four
sampl
base
sequenc
correspond
averag
coverag
depth
nucleotid
posit
compar
statist
signific
minor
variant
defin
pvalu
follow
multipletest
correct
benjaminihochberg
untreat
sarsexon
popul
follow
treatment
mm
figur
increas
mutat
within
sarsexon
popul
contrast
mutat
present
within
popul
compar
mutat
untreat
popul
increas
remark
repres
increas
number
statist
signific
minor
variant
treat
exon
sarscov
thu
data
support
hypothesi
increas
genom
mutat
incorpor
fump
viral
genom
absenc
exon
activ
chang
titer
fill
bar
genom
rna
level
hatch
bar
mhvexon
blue
green
virus
follow
treatment
shown
dbt
cell
infect
mhvexon
presenc
absenc
viru
titer
determin
plaqu
assay
genom
rna
level
determin
use
twostep
realtim
qrtpcr
primer
optim
amplifi
nt
region
chang
genom
rna
level
shown
rel
endogen
gapdh
express
normal
rna
level
untreat
sampl
mean
valu
sem
shown
n
part
statist
signific
determin
use
unpair
twotail
student
test
atog
utoc
transit
highli
repres
distribut
across
genom
incorpor
fump
instead
uracil
replic
rna
allow
fump
base
pair
guanosin
adenin
decreas
specif
base
pair
shown
studi
lcmv
primarili
result
atog
g
utoc
u
c
transit
determin
fump
incorpor
higher
level
absenc
exonmedi
proofread
analyz
number
type
transit
transvers
occur
viru
popul
figur
transit
indic
grey
box
transvers
white
box
number
shown
transvers
compris
major
variant
untreat
exon
virus
treatment
caus
number
u
c
g
transit
increas
exon
popul
sarsexon
figur
b
increas
bia
toward
u
c
g
transit
consist
fump
incorpor
minusand
plusstrand
rna
exon
replic
howev
absolut
number
dramat
increas
replic
compar
exon
untreat
cell
g
u
c
transit
account
less
total
minor
variant
within
popul
figur
follow
treatment
g
u
c
transit
account
total
minor
variant
within
popul
examin
genom
distribut
two
transit
plot
total
number
g
u
c
transit
occur
frequenc
figur
approxim
total
minor
variant
occur
frequenc
follow
treatment
due
g
u
c
transit
figur
sarsexon
popul
respect
popul
mutat
distribut
across
entir
genom
follow
treatment
mm
thu
data
provid
direct
evid
indic
drive
increas
genom
mutat
within
sarscov
absenc
exon
proofread
activ
panel
ac
statist
signific
determin
use
unpair
twotail
student
test
discuss
viral
sensit
rna
mutagen
determin
sever
factor
includ
polymeras
select
mutat
robust
acquisit
mutat
increas
decreas
replic
fidel
increas
decreas
fidel
mutant
describ
picornavirus
arbovirus
occur
viral
rdrp
cov
first
identifi
rna
viru
protein
distinct
rdrp
affect
replic
fidel
mutat
within
chikungunya
chikv
nonstructur
protein
implic
chikv
resist
rbv
direct
role
protein
fidel
regul
describ
sindbi
viru
variant
contain
mutat
within
viral
guanylyland
methyltransferas
shown
resist
rbv
mpa
howev
phenotyp
relat
viral
rna
cap
replic
fidel
report
identifi
cov
exon
activ
critic
determin
viral
sensit
rna
mutagen
use
two
phylogenet
distant
bcov
demonstr
phenotyp
well
conserv
across
cov
clearli
profound
increas
overal
mutat
specif
mutat
within
popul
compar
exon
wildtyp
popul
furthermor
vast
major
statist
signific
mutat
distribut
genomewid
frequenc
provid
strong
evid
support
exonmedi
proofread
cov
replic
interest
experi
also
reveal
exonmedi
prevent
andor
remov
misincorpor
nucleotid
absolut
especi
set
higher
concentr
mutagen
exon
sarscov
popul
demonstr
mutat
follow
treatment
suggest
exon
proofread
overwhelm
higher
concentr
mutagen
like
nucleosid
base
analog
rais
possibl
exon
may
less
effici
recogn
remov
type
nucleosid
base
analog
other
approach
viru
inhibit
might
viabl
particularli
combin
inhibitor
target
exon
activ
antivir
nucleosid
analog
rbv
current
use
treat
hepat
c
viru
hcv
lassa
viru
respiratori
syncyti
viru
rsv
infect
potenti
clinic
use
rbv
cov
infect
complic
multipl
mechan
action
report
potenti
diseas
exacerb
report
sarscov
epidem
data
suggest
rbv
primarili
inhibit
viru
replic
decreas
viral
rna
synthesi
inhibit
impdh
figur
inhibit
impdh
rmp
shown
decreas
intracellular
gtp
pool
thu
alter
balanc
nucleosid
triphosph
ntp
within
cell
decreas
gtp
level
could
result
forc
misincorpor
due
ntp
imbal
absenc
exon
activ
howev
moder
decreas
rel
specif
infect
observ
follow
rbv
treatment
tabl
suggest
mutagenesi
primari
mechan
rbv
exert
antivir
effect
addit
possibl
antivir
activ
rbv
virus
unrel
put
proofread
function
enzym
biochem
cell
cultur
studi
demonstr
loss
exon
activ
lead
impair
rna
synthesi
furthermor
addit
exon
activ
contain
activ
critic
step
rna
cap
recent
report
demonstr
exon
domain
structur
insepar
residu
within
exon
domain
import
activ
thu
increas
sensit
rbv
could
result
impair
undefin
function
exon
cov
replic
particularli
rna
synthesi
parallel
use
exon
virus
rbv
may
allow
us
defin
rbv
exert
antivir
effect
cov
potenti
novel
mechan
exon
may
act
counter
inhibit
sinc
identif
activ
studi
demonstr
requir
exon
highfidel
replic
mount
evid
point
role
proofread
activ
rna
viru
replic
use
ng
determin
number
mutat
present
sarsexon
popul
characterist
transit
u
c
g
compris
total
statist
signific
minor
variant
within
popul
present
level
higher
transit
within
exon
popul
figur
overal
data
repres
first
direct
test
exon
proofread
sarscov
replic
absenc
exon
furthermor
sequenc
depth
attain
use
ng
show
exon
inactiv
like
skew
spectrum
spontan
mutat
present
within
untreat
popul
figur
overrepresent
specif
mutat
context
exon
inactiv
similar
studi
cerevisia
dna
polymeras
e
contain
mutat
within
respect
dedd
exonucleas
alter
distribut
due
exon
inactiv
could
profound
implic
cov
adapt
evolut
lethal
mutagenesi
occur
accumul
mutat
within
viral
genom
replic
ultim
result
viru
extinct
review
lethal
mutagenesi
studi
extens
work
first
identifi
rna
viru
protein
distinct
rdrp
directli
regul
sensit
rna
virus
genom
mutat
result
mutagen
incorpor
current
rbv
fdaapprov
antivir
demonstr
mutagen
activ
first
demonstr
rbv
act
mutagen
perform
use
polioviru
almost
year
antivir
activ
rbv
describ
nucleosid
analog
favipiravir
current
clinic
develop
shown
recent
drive
lethal
mutagenesi
influenza
viru
shown
exon
virus
replic
well
presenc
rbv
howev
also
shown
mutant
sarscov
mhv
decreas
fidel
attenu
subject
rapid
loss
replic
clearanc
vivo
highli
suscept
low
concentr
rna
mutagen
excit
possibl
conserv
cov
proofread
enzym
could
target
inhibit
thu
lead
develop
broadli
use
cov
therapeut
exon
inhibitor
alon
might
efficaci
combin
inhibitor
cov
fidel
rna
mutagen
would
magnifi
intrins
fidel
defect
exon
inhibit
drive
highlevel
mutagenesi
potenti
advantag
approach
would
rapidli
drive
viru
extinct
limit
block
capac
viru
overcom
inhibit
revers
mutant
mhv
sarscov
shown
revers
multipl
passag
cultur
persist
infect
vivo
furthermor
observ
primari
revers
within
exon
dedd
motif
follow
treatment
mutat
within
cov
rdrp
could
emerg
acut
treatment
mutat
within
rna
viru
rdrp
demonstr
maximum
toler
increas
decreas
fidel
without
loss
viru
viabil
addit
data
demonstr
virus
profoundli
sensit
inhibit
lower
concentr
mutagen
provid
possibl
improv
therapeut
index
margin
safeti
use
summari
studi
provid
direct
evid
date
cov
exon
provid
proofread
function
viru
replic
identifi
exon
critic
determin
cov
sensit
rna
mutagen
cov
replic
fidel
like
determin
concert
effort
multipl
viru
protein
data
suggest
excit
possibl
signific
attenu
cov
fit
pathogenesi
could
achiev
target
conserv
process
cov
replic
fidel
ultim
uncov
mechan
fidel
regul
methodolog
disrupt
critic
process
vital
respond
endem
futur
emerg
cov
sarscov
merscov
